Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 19, 2017, Pages 4993-4998

  Kamphorst, Alice O ^a   Pillai, Rathi N ^a   Yang, Shu ^a,c   Nasti, Tahseen H ^a   Akondy, Rama S ^a   Wieland, Andreas ^a   Sica, Gabriel L ^a   Yu, Ke ^a   Koenig, Lydia ^a   Patel, Nikita T ^a   Behera, Madhusmita ^a   Wu, Hong ^a   McCausland, Megan ^a   Chen, Zhengjia ^b   Zhang, Chao ^b   Khuri, Fadlo R ^a,d   Owonikoko, Taofeek K ^a   Ahmed, Rafi ^a   Ramalingam, Suresh S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Cancer immunotherapy; CD8 T cells; Checkpoint inhibition; PD 1; T cell exhaustion

Indexed keywords

BLOCKING ANTIBODY; CD27 ANTIGEN; CD28 ANTIGEN; CD38 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; KI 67 ANTIGEN; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN BCL 2; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; DISEASE COURSE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NON SMALL CELL LUNG CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LUNG TUMOR; LYMPHOCYTE ACTIVATION; MALE; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85019093717     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1705327114     Document Type: Article

References (33)

1. Zajac AJ, et al. (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188:2205-2213.
2. Gallimore A, et al. (1998) Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major his-tocompatibility complex class I-peptide complexes. J Exp Med 187:1383-1393.
3. Barber DL, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687.
4. Wherry EJ (2011) T cell exhaustion. Nat Immunol 12:492-499.
5. Yokosuka T, et al. (2012) Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 209:1201-1217.
6. Pauken KE, Wherry EJ (2015) Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36:265-276.
7. Hui E, et al. (2017) T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355:1428-1433.
8. Callahan MK, Postow MA, Wolchok JD (2016) Targeting T cell co-receptors for cancer therapy. Immunity 44:1069-1078.
9. Topalian SL, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454.
10. Taube JM, et al. (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064-5074.
11. Herbst RS, et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-567.
12. Tumeh PC, et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-571.
13. Gerdes J, et al. (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715.
14. Goronzy JJ, Fang F, Cavanagh MM, Qi Q, Weyand CM (2015) Naive T cell maintenance and function in human aging. J Immunol 194:4073-4080.
15. Duraiswamy J, et al. (2011) Phenotype, function, and gene expression profiles of programmed death-1 (hi) CD8 T cells in healthy human adults. J Immunol 186:4200-4212.
16. Miller JD, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28:710-722.
17. Akondy RS, et al. (2009) The yellow fever virus vaccine induces a broad and poly-functional human memory CD8+ T cell response. J Immunol 183:7919-7930.
18. Kamphorst AO, et al. (2017) Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355:1423-1427.
19. Daud AI, et al. (2016) Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest 126:3447-3452.
20. Ahmadzadeh M, et al. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-1544.
21. Rizvi NA, et al. (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128.
22. Gubin MM, etal. (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577-581.
23. van Rooij N, et al. (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31:e439-e442.
24. Snyder A, et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199.
25. Tran E, Robbins PF, Rosenberg SA (2017) 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol 18:255-262.
26. Gros A, et al. (2014) PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124:2246-2259.
27. Gros A, et al. (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22:433-438.
28. Larkin J, et al. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34.
29. Postow MA, et al. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-2017.
30. Wolchok JD, etal. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133.
31. Im SJ, et al. (2016) Defining CD8+T cells that provide the proliferative burst after PD-1 therapy. Nature 537:417-421.
32. Chen PL, et al. (2016) Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6:827-837.
33. Ribas A, et al. (2016) PD-1 blockade expands intratumoral memory T cells. Cancer Immunol Res 4:194-203.